• David Cisewski, Brit Long, and Michael Gottlieb.
• Kaiser Permanente Santa Clara Homestead Medical Center, 700 Lawrence Expwy, Santa Clara, CA, USA.
• Am J Emerg Med. 2022 Mar 1; 53: 180-184.

IntroductionDroperidol is a butyrophenone that has recently been reintroduced after a United States Food and Drug Administration (US FDA) black box warning in 2001. Evidence demonstrates utility in a variety of clinical conditions.ObjectiveThis paper provides evidence-based updates concerning the use of droperidol for the emergency clinician.DiscussionDroperidol received a black box warning by the US FDA in 2001 due to concerns for QT prolongation and torsades de pointes; however, reevaluation of the available data suggests droperidol is a safe and efficacious medication. It can be used in the emergency department (ED) setting for many conditions, including acute agitation, headaches, vertigo, nausea, and vomiting. Extensive literature supports that the QT-prolonging effects are transient and that the risk of torsades de pointes is rare with doses utilized in the ED. An electrocardiogram does not need to be routinely obtained before droperidol use but should be considered in patients at high risk for QT prolongation.ConclusionsCurrent evidence suggests that droperidol is a safe and effective medication for treating nausea and vomiting, headache, vertigo, and agitation in the ED setting.Published by Elsevier Inc.

31 keywords...

hide…